Saturday, May 9, 2009

Mental Health: Comes With FREE Sudden DEATH

There's a New Medicine in town, and it's name is Fanapt: but First:

All 23 of the Psychiatric Poisons in our FDA Adverse Reaction section feature Sudden Death as an FDA reported Adverse Reaction with each Drug Individually identified as 'The Primary Suspect Drug' responsible for that Adverse Reaction

Abilify: Sudden Cardiac Death, Sudden Death

Adderall: Sudden Cardiac Death, Sudden Death
Celexa: Sudden Cardiac Death, Sudden Death, Sudden Infant Death Syndrome
Clozapine: Sudden Cardiac Death, Sudden Death
Cymbalta: Sudden Death
Depakote: Sudden Death
Effexor: Sudden Cardiac Death, Sudden Death
Geodon: Sudden Cardiac Death, Sudden Death
Klonopin: Sudden Death
Lamactil: Sudden Cardiac Death, Sudden Death, Sudden Infant Death Syndrome, Sudden Unexplained Death In Epilepsy
Lexapro: Sudden Cardiac Death, Sudden Death
Neurontin: Sudden Cardiac Death, Sudden Death
Paxil: Sudden Cardiac Death, Sudden Death
Prozac: Sudden Cardiac Death, Sudden Death
Risperdal: Sudden Cardiac Death, Sudden Death, Sudden Unexplained Death In Epilepsy
Ritalin/Concerta: Sudden Cardiac Death, Sudden Death
Seroquel: Sudden Cardiac Death, Sudden Death
Strattera: Sudden Death
Tegretol: Sudden Death
Wellbutrin: Sudden Death, Sudden Infant Death Syndrome
Xanax: Sudden Death
Zoloft: Sudden Death
Zyprexa: Sudden Cardiac Death, Sudden Death


It's FDA Label Time, for the Atypical Antipsychotics.

08/14/2008 Abilify pg 53

The mechanism of action of aripiprazole, as with other drugs having efficacy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder, and agitation associated with Schizophrenia or Bipolar Disorder, is unknown. However, it has been proposed that the efficacy of aripiprazole is mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. Actions at receptors other than D2, 5-HT1A, and 5-HT2A may explain some of the other clinical effects of aripiprazole (eg, the orthostatic hypotension observed with aripiprazole may be explained by its antagonist activity at adrenergic alpha1 receptors).



0:26 "Call your Doctor if you have," ..... the Ability remaining to even Reach for the phone.

10/02/2007 Geodon pg 2

The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown.

05/13/2008 Seroquel pg 34

The mechanism of action of SEROQUEL, as with other drugs having efficacy in the treatment of schizophrenia and bipolar disorder, is unknown. However, it has been proposed that the efficacy of SEROQUEL in schizophrenia and its mood stabilizing properties in bipolar depression and mania are mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other effects of SEROQUEL.

08/22/2007 Risperdal pg 36

The mechanism of action of RISPERDAL®, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.

03/19/2009 Zyprexa pg 24

The mechanism of action of olanzapine, as with other drugs having efficacy in Schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in Schizophrenia is mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of action of olanzapine in the treatment of acute manic or mixed episodes associated with Bipolar I Disorder is unknown.

So long as we let Govt keep Funding Old "D2/5HT2 Imbalance" here, Psychiatry is Going to keep Beating it,


and Promising that their "Mechanism of Action is Unknown" is going to get up yet, and Incurably Bio-$cience the whole damn Kentucky Derby, ..... someday. So Send More Money. They're short 2 bats.

But Wait! A Brand New MEDICINE, Unlike Anything Seen Before, is being Rushed to America's aid, thanks to our tireless PDUFA-crats at FDA.

FDA Approves Vanda Pharmaceuticals Fanapt

"Fanapt is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist, and belongs to the class of atypical antipsychotics."

And let's not Forget, in case the Other Atypicals don't work, and you somehow miraculously manage to Live through them:

06/29/2005 Clozaril pg 3

CLOZARIL® (clozapine) is classified as an ‘atypical’ antipsychotic drug because its profile of binding to dopamine receptors and its effects on various dopamine mediated behaviors differ from those exhibited by more typical antipsychotic drug products. In particular, although CLOZARIL does interfere with the binding of dopamine at D1, D2, D3 and D5 receptors, and has a high affinity for the D4 receptor, it does not induce catalepsy nor inhibit apomorphine-induced stereotypy. This evidence, consistent with the view that CLOZARIL is preferentially more active at limbic than at striatal dopamine receptors, may explain the relative freedom of CLOZARIL from extrapyramidal side effects.

All will be well. Trust in the System. Just SEND MORE MONEY. (Reuters)

No comments: